GlassScriptPhysician profile
Anthony D Duk
NPI 1154439131
$14,314.41
in general payments reported to CMS, 2019-2025
34 companies · $4,032 in 2025
The $4,032 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,675 · 2020: $408 · 2021: $1,191 · 2022: $2,434 · 2023: $2,267 · 2024: $2,307 · 2025: $4,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,528 · Education: $77.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,527.83 |
| Education | $77.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,075.46 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,839.44 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,643.05 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $1,384.45 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $983.72 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Indivior INC. | $950.72 | 2019-2024 | Perseris |
| Neurocrine Biosciences, INC. | $803.35 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $755.26 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $651.38 | 2021-2025 | Caplyta |
| Lundbeck LLC | $554.31 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $467.44 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $359.39 | 2019-2023 | Trintellix |
| Almatica Pharma LLC | $256.35 | 2021-2025 | Loreev Xr |
| Corium, LLC | $246.08 | 2022-2024 | Azstarys, Azstarys |
| Vanda Pharmaceuticals INC. | $194.17 | 2019-2025 | Fanapt, Hetlioz |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $153.24 | 2019-2020 | |
| Bausch Health US, LLC | $151.82 | 2020-2025 | Aplenzin |
| Noven Therapeutics, LLC | $147.96 | 2022-2025 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $143.20 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $122.16 | 2019-2022 | |
| Axsome Therapeutics, INC. | $110.86 | 2023-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $76.55 | 2019-2022 | |
| Sage Therapeutics, LLC | $35.43 | 2024 | |
| Tris Pharma INC | $30.27 | 2024 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $28.41 | 2021 | |
| Owp Pharmaceuticals, INC. | $25.53 | 2021 | |
| Novo Nordisk INC | $21.00 | 2025 | |
| Tonix Medicines, INC. | $17.11 | 2025 | Tonmya |
| Idorsia Pharmaceuticals US INC | $16.00 | 2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $15.89 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.16 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Collegium Pharmaceutical, INC. | $13.85 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $13.59 | 2020 | |
| Eisai INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Duk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.